HE
Hester Biosciences Ltd (HESTERBIO)
₹2,289.30
Mkt cap
₹1,868 Cr
P/E ratio
35.20
P/B
5.41
Div yield
0.50%
ROE
15.90%
ROCE
15.20%
EPS (TTM)
₹65.04
Book value
₹423
52W range
1,239–2,684
Sector
Healthcare
Price history
Previous close
Incorporated in 1987, Hester Biosciences Ltd is one of India’s leading animal healthcare companies and a major manufacturer of poultry and animal vaccines, including a leading position in PPR and Goat Pox vaccines. [1]
NSE HESTERBIOBSE 524669
Health check
Constructive
ValuationFair
ProfitabilityStrong
GrowthModerate
TechnicalsBullish
52-week range
−14.69% from high₹2,289
₹1,239+84.73% from low₹2,684
Current
₹2,289.30
Prev close
₹2,307.60
Day
−0.79%
Price performance
1D
+0.06%
1W
+12.27%
1M
+6.65%
3M
−6.83%
6M
+39.47%
1Y
+34.58%
YTD
+42.71%
Financials
Revenue, profit & margin
P/E ratio
35.2×
HESTERBIO is 2% above the sector median of 34.6×
HESTERBIO35.2×
Sector median34.6×
| Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Trend | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 88 | 70 | 67 | 79 | 82 | 84 | 63 | 82 | 84 | 71 | 77 | 100 | 77 | |
| Expenses | 73 | 57 | 57 | 63 | 65 | 65 | 58 | 63 | 61 | 59 | 60 | 66 | 54 | |
| Operating Profit | 14 | 13 | 10 | 16 | 18 | 19 | 5 | 19 | 23 | 12 | 18 | 34 | 23 | |
| OPM % | 16% | 19% | 15% | 20% | 21% | 23% | 8% | 23% | 27% | 17% | 23% | 34% | 29% | |
| Other Income | 3 | 6 | 2 | 5 | 2 | 3 | 9 | -6 | 3 | 12 | 2 | 2 | 89 | |
| Interest | 3 | 8 | 2 | 7 | 5 | 6 | -4 | 6 | 2 | 2 | 2 | 5 | 3 | |
| Depreciation | 5 | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 6 | 7 | |
| Profit before tax | 9 | 7 | 6 | 10 | 11 | 12 | 13 | 4 | 20 | 17 | 14 | 25 | 102 | |
| Tax % | 25% | 40% | 37% | 35% | 29% | 29% | 15% | 59% | 14% | 16% | 31% | 34% | 5% | |
| Net Profit | 7 | 4 | 4 | 6 | 7 | 8 | 11 | 2 | 17 | 14 | 9 | 17 | 97 | |
| EPS in Rs | 6.90 | 4.81 | 4.68 | 5.82 | 7.45 | 9.64 | 13.71 | 1.52 | 19.33 | 16.99 | 10.31 | 18.78 | 114.00 | |
| Raw PDF |
Earnings
Results dates & reactionsNext results
5 Nov '26
Fresh quarters land in the Financials table above, tagged NSE until screener catches up.
Avg earnings-day move −0.75% · closed higher next day 0 of last 1
| Q1FY27 | |
|---|---|
| Broadcast | 30 Jul '26 |
| Earnings day | −0.75% |
| +1 day | −0.77% |
| +5 days | −1.54% |
| +15 days | −3.36% |
| +30 days | −8.73% |
| Filing | XBRL |
Corporate actions
Last 6 monthsNo recent corporate actions
Dividends, splits, and bonuses in the last six months show up here.
Shareholding
as of Jun 202653.73%Promoter
Promoters53.73%
FIIs0.31%0.07
DIIs0.00%
Public45.95%0.07
Ownership trend
Peers
8 companiesValuation vs quality
P/E × ROCE · bubble = market cap| Name | CMP | P/E | Mkt Cap | Div Yld | NP Qtr | Qtr Profit Var | Sales Qtr | Qtr Sales Var | ROCE |
|---|---|---|---|---|---|---|---|---|---|
| Sun Pharma.Inds. | ₹1,837.30 | 34.90 | 4,40,830 | 0.87% | 2,901 | +5.95% | 15,300 | +10.46% | 20.53% |
| Divi's Lab. | ₹9,375.00 | 83.54 | 2,48,877 | 0.32% | 902 | +65.50% | 3,080 | +27.80% | 21.97% |
| Torrent Pharma. | ₹4,840.00 | 82.51 | 1,84,098 | 0.79% | 566 | +5.79% | 4,921 | +54.85% | 15.19% |
| Zydus Lifesci. | ₹1,160.00 | 23.77 | 1,15,710 | 0.09% | 990 | −35.09% | 8,017 | +21.96% | 21.14% |
| Cipla | ₹1,394.50 | 31.48 | 1,12,656 | 0.93% | 786 | −39.19% | 7,119 | +2.33% | 15.49% |
| Laurus Labs | ₹1,954.00 | 96.56 | 1,05,577 | 0.10% | 362 | +125.49% | 2,026 | +29.10% | 17.76% |
| Aurobindo Pharma | ₹1,734.00 | 26.39 | 99,771 | 0.23% | 1,032 | +28.11% | 9,150 | +16.30% | 12.86% |
| Hester Bios | ₹2,195.60 | 35.16 | 1,868 | 0.50% | 97 | −3.95% | 77 | −8.17% | 15.25% |
| Median: 158 Co. | ₹433.90 | 34.56 | 2,205 | 0.08% | 13 | +29.57% | 164 | +18.57% | 14.96% |
Filings
Annual reports15
Concall transcripts50
TranscriptAug 2026RECAug 2026TranscriptMay 2026PPTMay 2026RECMay 2026TranscriptJan 2026RECJan 2026TranscriptNov 2025TranscriptAug 2025TranscriptMay 2025TranscriptFeb 2025RECFeb 2025TranscriptOct 2024TranscriptAug 2024TranscriptMay 2024RECMay 2024TranscriptFeb 2024RECFeb 2024TranscriptNov 2023RECNov 2023RECNov 2023TranscriptAug 2023TranscriptMay 2023TranscriptFeb 2023
Credit ratings6
Announcements5
Shareholders' Approval For Reclassification From 'Promoter And Promoter Group' Category To 'Public' Category Shareholders 4 Sep - Shareholders approved reclassification of Ravin Gandhi and Bela Gandhipromoter to public on 3 September 2026.Shareholder Meeting / Postal Ballot-Scrutinizer"s Report 4 SepShareholder Meeting / Postal Ballot-Outcome of Postal_Ballot 4 SepAnnouncement under Regulation 30 (LODR)-Credit Rating 27 Aug - CARE upgraded Hester Biosciences’ bank ratings to BBB+/Stable and A2 on 27 August 2026.Shareholder Meeting / Postal Ballot-Notice of Postal Ballot 4 Aug - Postal ballot on reclassifying Ravin Gandhi and Bela Gandhipromoter to public shareholders.